The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Ruxolitinib for Chronic Neutrophilic Leukemia

JAK1/2 inhibitor in CSF3R T618I-mutated rare myeloproliferative neoplasm

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Ruxolitinib for Chronic Neutrophilic Leukemia?

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm with sustained mature neutrophilia.

CSF3R T618I activating mutation drives JAK-STAT signaling and is present in over 80 percent of CNL cases.

Distinguished from chronic myelomonocytic leukemia and atypical chronic myeloid leukemia by molecular profile.

Hepatomegaly, splenomegaly, and bone marrow hypercellularity with neutrophilic predominance characterize disease.

Ruxolitinib targets downstream JAK-STAT signaling, providing a rational therapeutic approach in CSF3R-mutated cases.

Symptoms

Marked persistent peripheral neutrophilia (often greater than 25000 per microliter).
Splenomegaly and hepatomegaly causing abdominal discomfort.
Constitutional symptoms: fatigue, weight loss, fevers, sweats.
Bone pain from medullary expansion.
Easy bruising and bleeding tendencies in advanced disease.

Risk Factors

CSF3R T618I mutation positive on molecular testing.
Older age at diagnosis (median 65 to 70 years).
Coexisting plasma cell disorder (monoclonal gammopathy) in some cases.
Concurrent SETBP1 or ASXL1 mutations may worsen prognosis.
Disease progression to acute myeloid leukemia possible.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent unexplained neutrophilia on serial complete blood counts.
  • New abdominal fullness or splenomegaly during evaluation.
  • Constitutional symptoms with progressive weight loss.
  • Cytopenias developing during follow-up suggesting transformation.
  • Loss of response while receiving therapy.

Treatment Methods

01
Hydroxyurea remains a common first-line cytoreductive option for symptom control.
02
Ruxolitinib 5 to 20 mg orally twice daily showing benefit in CSF3R T618I-mutated cases.
03
Allogeneic hematopoietic stem cell transplantation considered in eligible patients with high-risk disease.
04
Interferon alfa as alternative cytoreduction in selected patients.
05
Clinical trials of dasatinib and other targeted agents ongoing for resistant disease.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.